A toxic mushroom is gaining popularity: amanita muscaria is marketed as a safe psychedelic despite high toxicity and unverified health claims

Amanita muscaria is gaining popularity as a “psychedelic” alternative, but public health concerns point to its serious toxicity and lack of proven medical value. The opinion argues that products are widely sold with sweeping claims about treating anxiety, depression, sleep issues, and enhancing creativity, while amanita is not regulated like federally controlled psilocybin. It also highlights that people may not know what they are actually ingesting because labeling can be inaccurate and dosage is effectively arbitrary. It cites harm reports including a 2024 rash of muscimol related illnesses across multiple states, plus testing findings that products marketed as amanita can contain psilocybin and other unlabeled prescription drugs. The piece calls for stronger consumer protections such as age restrictions, limits on marketing that targets children, mandatory testing, and improved public education to distinguish legitimate psilocybin research from unverified amanita marketing.